Acorda Therapeutics to Provide Pipeline Update at Upcoming R&D Day

Acorda Therapeutics, Inc. (Nasdaq: ACOR)
will host a Research and Development Day for the investment community on
Tuesday, April 17, 2012 from 10:00 a.m. to 1:00 p.m. at The Four Seasons
Hotel in New York City.

Members of Acorda’s management team, including President and CEO Ron
Cohen, M.D., Chief Scientific Officer Andrew Blight, Ph.D., Chief
Medical Officer Enrique Carrazana., M.D., and VP, Research and
Development Tony Caggiano, Ph.D, M.D., will review Acorda’s current R&D
programs including its AMPYRA® (dalfampridine) Extended
Release Tablets, 10 mg stroke, cerebral palsy and other development
programs, as well as its other clinical and preclinical programs.
Independent experts in the fields of heart failure, spinal cord injury
and chronic stroke will provide perspectives on current standards of
care and the compounds being developed by Acorda.

A live audio webcast of the presentation can be accessed under “Investor
Events” in the Investor section of the Acorda website at www.acorda.com
or available via the following link prior to the start of the event:

To participate in the conference call, please dial 800-798-2796
(domestic) or 617-614-6204 (international) and reference the access code
48961682. A replay of the call will be available from 3:30 p.m. on April
17, 2012 until 11:59 p.m. on May 17, 2012. To access the replay, please
dial 888-286-8010 (domestic) or 617-801-6888 (international) and
reference the access code 77122833.

Acorda Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with MS,
spinal cord injury and other neurological conditions.

Acorda markets AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, in the United
States as a treatment to improve walking in patients with multiple
sclerosis (MS). This was demonstrated by an improvement in walking
speed. AMPYRA is marketed outside the United States as FAMPYRA®
(prolonged-release fampridine tablets) by Biogen Idec under a licensing
agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license
from Alkermes Pharma Ireland Limited.

The Company also markets ZANAFLEX
CAPSULES® (tizanidine hydrochloride) and ZANAFLEX®
(tizanidine hydrochloride) tablets, a short-acting drug for the
management of spasticity. Acorda also receives sales royalties on
tizanidine hydrochloride tablets, an authorized generic version of
ZANAFLEX CAPSULES distributed by Watson Pharmaceutics, Inc. under its
agreement with Acorda.

Acorda is developing an industry-leading pipeline of novel neurological
therapies. The Company is studying AMPYRA to improve a range of
functional impairments caused by MS, as well as its use in other
neurological conditions, including cerebral palsy and chronic stroke. In
addition, Acorda is developing clinical stage compounds AC105 for acute
treatment of spinal cord injury and GGF2 for treatment of heart
failure. GGF2 is also being investigated in preclinical studies as a
treatment for neurological conditions such as stroke and spinal cord
injury. Additional preclinical programs include rHIgM22, a remyelinating
monoclonal antibody for the treatment of MS, and chondroitinase, an
enzyme that encourages nerve plasticity in spinal cord injury.

Forward-Looking Statements

This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including Acorda Therapeutics' ability to successfully market and sell
Ampyra in the United States; third party payors (including governmental
agencies) may not reimburse for the use of Ampyra at acceptable rates or
at all and may impose restrictive prior authorization requirements that
limit or block prescriptions; the risk of unfavorable results from
future studies of Ampyra; the occurrence of adverse safety events with
our products; delays in obtaining or failure to obtain regulatory
approval of or to market successfully Fampyra outside of the United
States and our dependence on our collaboration partner Biogen Idec in
connection therewith; competition, including the impact of generic
competition on Zanaflex Capsules revenues; failure to protect Acorda
Therapeutics’ intellectual property, to defend against the intellectual
property claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; the ability
to obtain additional financing to support Acorda Therapeutics'
operations; and, unfavorable results from our research and development
programs. These and other risks are described in greater detail in
Acorda Therapeutics' filings with the Securities and Exchange
Commission. Acorda Therapeutics may not actually achieve the goals or
plans described in its forward-looking statements, and investors should
not place undue reliance on these statements. Forward-looking statements
made in this release are made only as of the date hereof, and Acorda
Therapeutics disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.